PET vendor Positron said that its wholly owned subsidiary Manhattan Isotope Technology (MIT) has completed the first commercial sale and delivery of its active pharmaceutical ingredient (API)-grade strontium-82 (Sr-82) to a North American pharmaceutical firm.
MIT processed, produced, and shipped the API-grade strontium-82, which is used to manufacture rubidium-82 (Rb-82) generators. The API Sr-82 was produced from target material received from one of MIT's foreign collaborators for target irradiation, according to Positron.
Positron said it has reaffirmed its commitment to Rb-82-based cardiac PET by addressing Sr-82 production, the largest single factor limiting its growth.
